Search Results - "Kornblau, S"

Adverse reactions to fluorescein angiography: A comprehensive review of the literature by Kornblau, Ilyse S., El-Annan, Jaafar F.

“…We reviewed literature on adverse reactions to intravenous fluorescein angiography using PubMed and found 78 articles in English from 1961 to 2017. The…”
Get full text

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML by DiNardo, C.D., Tiong, I.S., Quaglieri, A., MacRaild, S., Loghavi, S., Brown, F.C., Thijssen, R., Pomilio, G., Ivey, A., Salmon, J.M., Glytsou, C., Fleming, S.A., Zhang, Q., Ma, H., Patel, K.P., Kornblau, S.M., Xu, Z., Chua, C.C., Chen, Xufeng, Blombery, P., Flensburg, C., Cummings, N., Aifantis, I., Kantarjian, H., Huang, D.C.S, Roberts, A.W., Majewski, I.J., Konopleva, M., Wei, A.H.

“…The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for older or unfit patients with…”
Get full text

WTAP is a novel oncogenic protein in acute myeloid leukemia by Bansal, H, Yihua, Q, Iyer, S P, Ganapathy, S, Proia, D, Penalva, L O, Uren, P J, Suresh, U, Carew, J S, Karnad, A B, Weitman, S, Tomlinson, G E, Rao, M K, Kornblau, S M, Bansal, S

Get full text

p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status by Quintás-Cardama, A, Hu, C, Qutub, A, Qiu, Y H, Zhang, X, Post, S M, Zhang, N, Coombes, K, Kornblau, S M

“…TP53 mutations are associated with the lowest survival rates in acute myeloid leukemia (AML). In addition to mutations, loss of p53 function can arise via…”
Get full text

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies by Bogenberger, J M, Kornblau, S M, Pierceall, W E, Lena, R, Chow, D, Shi, C-X, Mantei, J, Ahmann, G, Gonzales, I M, Choudhary, A, Valdez, R, Camoriano, J, Fauble, V, Tiedemann, R E, Qiu, Y H, Coombes, K R, Cardone, M, Braggio, E, Yin, H, Azorsa, D O, Mesa, R A, Stewart, A K, Tibes, R

“…Synergistic molecular vulnerabilities enhancing hypomethylating agents in myeloid malignancies have remained elusive. RNA-interference drug modifier screens…”
Get full text

Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia by van Dijk, A D, Hoff, F W, Qiu, Y H, Chandra, J, Jabbour, E, de Bont, E S J M, Horton, T M, Kornblau, S M

“…Acute leukemia is an epigenetically heterogeneous disease. The intensity of treatment is currently guided by cytogenetic and molecular genetic risk…”
Get full text

Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD) by Sun, Q-Y, Ding, L-W, Tan, K-T, Chien, W, Mayakonda, A, Lin, D-C, Loh, X-Y, Xiao, J-F, Meggendorfer, M, Alpermann, T, Garg, M, Lim, S-L, Madan, V, Hattori, N, Nagata, Y, Miyano, S, Yeoh, A E J, Hou, H-A, Jiang, Y-Y, Takao, S, Liu, L-Z, Tan, S-Z, Lill, M, Hayashi, M, Kinoshita, A, Kantarjian, H M, Kornblau, S M, Ogawa, S, Haferlach, T, Yang, H, Koeffler, H P

“…Partial tandem duplication of MLL ( MLL-PTD ) characterizes acute myeloid leukemia (AML) patients often with a poor prognosis. To understand the order of…”
Get full text

Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients by Ruvolo, P P, Qui, Y H, Coombes, K R, Zhang, N, Ruvolo, V R, Borthakur, G, Konopleva, M, Andreeff, M, Kornblau, S M

“…The regulation of protein kinase B (AKT) is a dynamic process that depends on the balance between phosphorylation by upstream kinases for activation and…”
Get full text

Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155 by Lee, D W, Futami, M, Carroll, M, Feng, Y, Wang, Z, Fernandez, M, Whichard, Z, Chen, Y, Kornblau, S, Shpall, E J, Bueso-Ramos, C E, Corey, S J

“…The myelodysplastic syndromes (MDSs) comprise a group of disorders characterized by multistage progression from cytopenias to acute myeloid leukemia (AML)…”
Get full text

A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome by Kelly, A D, Kroeger, H, Yamazaki, J, Taby, R, Neumann, F, Yu, S, Lee, J T, Patel, B, Li, Y, He, R, Liang, S, Lu, Y, Cesaroni, M, Pierce, S A, Kornblau, S M, Bueso-Ramos, C E, Ravandi, F, Kantarjian, H M, Jelinek, J, Issa, J-PJ

“…Genetic changes are infrequent in acute myeloid leukemia (AML) compared with other malignancies and often involve epigenetic regulators, suggesting that an…”
Get full text

HOX expression patterns identify a common signature for favorable AML by Andreeff, M, Ruvolo, V, Gadgil, S, Zeng, C, Coombes, K, Chen, W, Kornblau, S, Barón, A E, Drabkin, H A

“…Deregulated HOX expression, by chromosomal translocations and myeloid-lymphoid leukemia (MLL) rearrangements, is causal in some types of leukemia. Using…”
Get full text

Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target by Alatrash, G, Garber, H R, Zhang, M, Sukhumalchandra, P, Qiu, Y, Jakher, H, Perakis, A A, Becker, L, Yoo, S Y, Dwyer, K C, Coombes, K, Talukder, A H, John, L S St, Senyukov, V, Lee, D A, Sergeeva, A, He, H, Ma, Q, Armistead, P M, Roszik, J, Mittendorf, E A, Molldrem, J J, Hawke, D, Lizee, G, Kornblau, S M

Get full text

Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics by Heinrichs, S, Kulkarni, R V, Bueso-Ramos, C E, Levine, R L, Loh, M L, Li, C, Neuberg, D, Kornblau, S M, Issa, J-P, Gilliland, D G, Garcia-Manero, G, Kantarjian, H M, Estey, E H, Look, A T

“…Progress in the management of patients with myelodysplastic syndromes (MDS) has been hampered by the inability to detect cytogenetic abnormalities in 40–60% of…”
Get full text

Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia by Madan, V, Shyamsunder, P, Han, L, Mayakonda, A, Nagata, Y, Sundaresan, J, Kanojia, D, Yoshida, K, Ganesan, S, Hattori, N, Fulton, N, Tan, K T, Alpermann, T, Kuo, M C, Rostami, S, Matthews, J, Sanada, M, Liu, L-Z, Shiraishi, Y, Miyano, S, Chendamarai, E, Hou, H A, Malnassy, G, Ma, T, Garg, M, Ding, L W, Sun, Q Y, Chien, W, Ikezoe, T, Lill, M, Biondi, A, Larson, R A, Powell, B L, Lübbert, M, Chng, W J, Tien, H F, Heuser, M, Ganser, A, Koren-Michowitz, M, Kornblau, S M, Kantarjian, H M, Nowak, D, Hofmann, W K, Yang, H, Stock, W, Ghavamzadeh, A, Alimoghaddam, K, Haferlach, T, Ogawa, S, Shih, L Y, Mathews, V, Koeffler, H P

Get full text

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia polycythemia vera myelofibrosis by Quintás-Cardama, A, Tong, W, Kantarjian, H, Thomas, D, Ravandi, F, Kornblau, S, Manshouri, T, Cortes, J E, Garcia-Manero, G, Verstovsek, S

“…Myelofibrosis (MF; primary or post-essential thrombocythemia/polycythemia vera) is incurable clonal myeloproliferative disorder, with no effective treatment…”
Get full text

Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies by ÖZDEMIR, E, SALIBA, R. M, SHPALL, E. J, QAZILBASH, M. H, MOLLDREM, J. J, CHEMALY, R. F, KOMANDURI, K. V, CHAMPLIN, R. E, COURIEL, D. R, GIRALT, S. A, DE LIMA, M, KHOURI, I. F, HOSING, C, KORNBLAU, S. M, ANDERLINI, P

“…We analyzed the clinical factors associated with late cytomegalovirus (CMV) reactivation in a group of 269 consecutive recipients of allogeneic stem cell…”
Get full text

Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma by Yang, L, Wang, H, Kornblau, S M, Graber, D A, Zhang, N, Matthews, J A, Wang, M, Weber, D M, Thomas, S K, Shah, J J, Zhang, L, Lu, G, Zhao, M, Muddasani, R, Yoo, S-Y, Baggerly, K A, Orlowski, R Z

“…Dysregulation of cyclin D2 contributes to the pathogenesis of multiple myeloma, and can occur through translocations that activate MAF / MAFB or MMSET/FGFR3 …”
Get full text

A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia by Hu, C. W., Qiu, Y., Ligeralde, A., Raybon, A. Y., Yoo, S. Y., Coombes, K. R., Qutub, A. A., Kornblau, S. M.

“…Acute myelogenous leukaemia (AML) is associated with risk factors that are largely unknown and with a heterogeneous response to treatment. Here, we provide a…”
Get full text

Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects by Milella, M, Precupanu, C M, Gregorj, C, Ricciardi, M R, Petrucci, M T, Kornblau, S M, Tafuri, A, Andreeff, M

“…The MEK/MAPK signaling module is a key integration point along signal transduction cascades that regulate cell growth, survival, and differentiation, and is…”
Get more information

Biological properties of ligand-dependent activation of the MET receptor kinase in acute myeloid leukemia by McGee, S F, Kornblau, S M, Qiu, Y, Look, A T, Zhang, N, Yoo, S-Y, Coombes, K R, Kentsis, A

Get full text